MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517040975 A) filed by Universitat Basel; and Eth Zurich, Basel, Switzerland, on April 28, for 'immunosuppressive compounds.'
Inventor(s) include Jayachandran, Rajesh; Pieters, Jean; Erni, Reto; Georgiev, Tony; Carreira, Erick M.; George, Pascal; and Jimenez Teja, Daniel.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relates to a process for the stereoselective preparation of such compounds. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a vector comprising a coronin 1 promoter element, wherein in a vertebrate genome, said coronin 1 promoter element starts directly upstream from a transcription starting site (TSS) of a coronin 1 gene and spans a sequence stretch of at least about 700 bp in said genome. The present invention further relates to a method using said vector for identifying immunomodulatory compounds that alter the coronin 1 promoter activity. The present invention further relates to BRD3 as an upstream target responsible for driving the coronin-1 expression and activity in immune cells, and relates to compounds, in particular compound of formula (I), that selectively target bromodomains of BRD3 and thereby deplete coronin 1 levels."
The patent application was internationally filed on Sept. 30, 2023, under International application No.PCT/EP2023/077188.
Disclaimer: Curated by HT Syndication.
